WASHINGTON, Sept. 3, 2019 /PRNewswire/ -- Danaher Corporation
(NYSE: DHR) ("Danaher") announced today that its wholly-owned
subsidiary, DH Europe Finance II S.à r.l. ("Danaher International
II"), has priced an offering of:
- €1,250,000,000 principal amount of 0.200% senior notes due 2026
at an offering price of 99.833% of the principal amount;
- €1,250,000,000 principal amount of 0.450% senior notes due 2028
at an offering price of 99.751% of the principal amount;
- €1,750,000,000 principal amount of 0.750% senior notes due 2031
at an offering price of 99.920% of the principal amount;
- €1,250,000,000 principal amount of 1.350% senior notes due 2039
at an offering price of 99.461% of the principal amount; and
- €750,000,000 principal amount of 1.800% senior notes due 2049
at an offering price of 99.564% of the principal amount
(collectively, the "senior notes").
Danaher estimates that the net proceeds from the sale of the
senior notes in this offering will be approximately €6.197 billion,
after deducting the underwriting discounts and estimated offering
expenses payable by Danaher. Danaher anticipates using the net
proceeds to fund a portion of the cash consideration payable for,
and certain costs associated with, its acquisition of the Biopharma
Business of GE Life Sciences (the "GE Biopharma Acquisition").
Pending completion of the GE Biopharma Acquisition, Danaher may
invest the net proceeds of the offering in short-term bank deposits
or invest them in interest-bearing, investment-grade securities.
The senior notes will be fully and unconditionally guaranteed on a
senior unsecured basis by Danaher. The offering is expected to
close on September 18, 2019, subject
to customary closing conditions.
The offering is being made pursuant to an effective shelf
registration statement on file with the U.S. Securities and
Exchange Commission.
The offering of senior notes may be made only by means of a
prospectus and prospectus supplement. A copy of the
prospectus and prospectus supplement relating to the securities can
be obtained from Barclays Bank PLC at Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Phone:
1-888-603-5847; BNP Paribas at 10 Harewood Avenue, London NW1 6AA, United Kingdom, Attention: Fixed Income
Syndicate, Phone: 1-800-854-5674; Citigroup Global Markets Limited
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717, by
calling 1 (800) 831-9146 or by email at prospectus@citi.com;
Deutsche Bank AG, London Branch at
Winchester House, 1 Great Winchester Street, London EC2N 2DB, Attention: Syndicate Desk,
Phone: +44-20-7545-4361, Fax: +44-20-7545-4455; or Banco Santander,
S.A., Ciudad Grupo Santander, Avenida de Cantabria s/n, Boadilla
del Monte, Madrid, Spain,
Attention: Syndicate Desk, Phone: +34-91-257-2029 or
+44-20-7756-6802.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, the senior notes or any other
securities, nor shall there be any offer, solicitation or sale of
any security mentioned in this press release in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
ABOUT DANAHER
Danaher is a global science and technology innovator committed
to helping its customers solve complex challenges and improving
quality of life around the world. Its family of world class brands
has leadership positions in the demanding and attractive health
care, environmental and applied end-markets. With more than 20
operating companies, Danaher's globally diverse team of
approximately 71,000 associates is united by a common culture and
operating system, the Danaher Business System, and its Shared
Purpose, Helping Realize Life's Potential.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical,
including the statements regarding the offering of the senior
notes, the anticipated use of proceeds and any other statements
regarding events or developments that we believe or anticipate will
or may occur in the future, may be "forward-looking statements"
within the meaning of the federal securities laws. There are a
number of important factors that could cause actual events to
differ materially from those suggested or indicated by such
forward-looking statements and you should not place undue reliance
on any such forward-looking statements. Additional information
regarding the factors that may cause actual results to differ
materially from these forward-looking statements is available in
Danaher's SEC filings, including Danaher's 2018 Annual Report on
Form 10-K and Danaher's Quarterly Reports on Form 10-Q for the
first and second quarters of 2019. These forward-looking statements
speak only as of the date of this release and Danaher and Danaher
International II do not assume any obligation to update or revise
any forward-looking statement, whether as a result of new
information, future events and developments or otherwise.
View original
content:http://www.prnewswire.com/news-releases/danaher-announces-pricing-of-euro-denominated-senior-notes-offering-300911150.html
SOURCE Danaher Corporation